Cardiovascular Revascularization Medicine
Volume 6, Issue 3 , Pages 92-98 , July 2005

Clinical and angiographic follow-up in patients with Cypher or Taxus stents in populations with high percentage of trial-excluded lesions

Received 17 July 2005 ,Accepted 17 July 2005.

References 

  1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  3. Ruiz-Nodar JM, Frutos A, Carrillo P, Morillas P, Valero R, Rodriguez JA, et al. Use of sirolimus-eluting stents in complex lesions: clinical and angiographic follow-up. Rev Esp Cardiol. 2004;57:123–129
  4. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Ramanycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital. RESARCH Registry. Circulation. 2004;109:190–195
  5. Goy JJ, Urban P, Seydoux C, De Benedetti E, Stauffer JC. Use of sirolimus-eluting coronary stents in routine clinical practice. Catheter Cardiovasc Interv. 2004;62:26–29
  6. Ferreira AC, Peter AA, Salerno TA, Bolooki H, de Marchena E. Clinical impact of drug-eluting stents in changing referral practices for coronary surgical revascularization in a tertiary care center. Ann Thorac Surg. 2003;75:485–489
  7. Faxon D. Bringing reality to drug-eluting stents. Circulation. 2004;109:140–142
  8. Berger PB, Costa MA, Cohen S, Peter C. Block, Duke Clinical Research Institute, Durham, NC. Six month clinical outcome using sirolimus eluting stents in clinical practice: results from US post marketing surveillance registry (the E-CYPHER Study). J Am Coll Cardiol. 2005;45(73A):1150–1231
  9. Zahn R, Hamm CW, Zeymer U, Schneider S, Nienaber CA, Richardt G, et al. “Real life” use of sirolimus-eluting coronary stents in Germany. Results from the prosspective multi-centre German Cypher Registry. Z Kardiol. 2004;93:287–294
  10. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130
  11. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol. 2004;43:585–591
  12. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS substudy. Circulation. 2004;109:2273–2278
  13. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow release, polymer based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942–1947
  14. Sabaté M, Jiménez Quevedo P, Angiolillo DJ, Alfonso F, Goicolea J, Fernández-Avilés F, et al. Sirolimus-eluting stent to prevent restenosis after stenting in diabetic patients with de novo coronary stenoses: the DIABETES (Diabetes and Sirolimus Eluting Stent) Trial: 9-month angiographic results. Am J Cardiol. 2004;94(6 Suppl 1):75E
  15. Finn AV, Palacios IF, Kastrati A, Gold HK. Drug eluting stents for diabetes mellitus. J Am Coll Cardiol. 2005;45:479–483
  16. Abizaid A, Chan C, Lim TT, Kaul U, Patel T, Cheem Tan H, et al. Wisdom high-risk subgroups: 12 month outcomes with the slow-release, polymer-based, paclitaxel-eluting taxus stent. J Am Coll Cardiol. 2005;45(A84):866–873
  17. Tarantini G, Briguori C, Stankovic G, Takagi T, Corvaja N, Di Mario C, et al. Insulin-treated diabetes mellitus and predictors of mid-term clinical outcome after percutaneous coronary interventions with stent implantation. Ital Heart J. 2003;4:843–849
  18. López-Mínguez JR, Merchán A, Poblador A, Romero R, Címbora A, Millán V, et al. Reopro use experience in stent implantations in a nonselected population with a high rate of unfavorable lesions. Am J Cardiol. 1998;82:94S–95S
  19. López-Mínguez JR, Nogales JM, Morales A, González R, Alonso R, Merchán A. Importance of the GPI IIb/IIIa in insulin dependent diabetic patients undergoing percutaneous coronary intervention. Rev Esp Cardiol. 2005;(Suppl):[in press]
  20. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283–1288
  21. Schuhlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, Dirschinger J, et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J. 2004;147:317–322
  22. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998;32:584–589
  23. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293:165–171
  24. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004;292:2727–2734
  25. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-Sirius). Lancet. 2003;362:1093–1099
  26. Stone GW, Ellis SG, O'Shaughnessy CD, Satler L, Martin S, McGarry T, et al. A prospective, multicenter randomized trial of the paclitaxel-eluting stent versus vascular brachytherapy in patients with coronary in-stent restenosis: the TAXUS-V ISR Trial. J Am Coll Cardiol. 2005;45(86A):857–863
  27. Degertekin M, Arampatzis CA, Lemos PA, Saia F, Hoye A, Daemen J, et al. Very long sirolimus-eluting stent implantation for de novo coronary lesions. Am J Cardiol. 2004;93:826
  28. Hoye A, Tanabe K, Lemos PA, Aoki J, Saia F, Arampatzis C, et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol. 2004;43:1954–1959
  29. Werner GS, Krack A, Schwarz G, Prochnau D, Betge S, Figulla HR. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J Am Coll Cardiol. 2004;44:2301–2306
  30. Ge L, Iakovou I, Cosgrave J, Chieffo A, Montorfano M, Michev I, et al. Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J. 2005;26:1056–1062
  31. Nakamura S, Muthusamy TS, Bae JH, Cahyadi YH, Udayachalerm W, Tresukosol D. Impact of sirolimus-eluting stent on the outcome of patients with chronic total occlusions. Am J Cardiol. 2005;95:161–166
  32. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR, Spanos V, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004;109:1244–1249
  33. Hoye A, van Mieghem C, Ong ATL, Aoki J, Rodríguez Granillo GA, Valgimigli M, et al. Percutaneous coronary intervention of the novo bifurcation lesions: therapy with sirolimus-eluting stents is associated with fewer major adverse cardiac events and target lesion revascularization compared with paclitaxel-eluting stent implantation. J Am Coll Cardiol. 2005;45(88A):876–885
  34. Huang HL, Hsieh IC, Chang SH, Chang HJ, Chen CC, Hung KC, et al. Acute and long-term outcomes of intracoronary stenting in aorto-ostial, left anterior descending artery-ostial and nonostial stenosis. Int J Cardiol. 2005;101:391–397
  35. Iakovou I, Ge L, Michev I, Sangiorgi GM, Montorfano M, Airoldi F, et al. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. J Am Coll Cardiol. 2004;44:967–971
  36. Sawhney N, Moses JW, Leon MB, Kuntz RE, Popma JJ, Bachinsky W, et al. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation. 2004;110:374–379
  37. Dangas G, Ellis SG, Shlofmitz R, Katz S, Fish D, Martin S, et al. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coll Cardiol. 2005;1186–1192
  38. Dietz U, Holz N, Dauer C, Lambertz H. Shortening the stent length reduces restenosis with bare metal stents: matched-pair comparison of short stenting and conventional stenting. Heart. 2005;[electronic publication ahead of print]
  39. Wong SC, Hong MK, Ellis SG, Buchbinder M, Reisman M, De Lago A, et al. Influence of stent length to lesion length ratio on angiographic and clinical outcomes after implantation of bare metal and drug-eluting stents (the TAXUS-IV Study). Am J Cardiol. 2005;95(9):1043–1048
  40. Tsagalou E, Chieffo A, Iakovou I, Ge L, Sangiorgi GM, Corvaja N, et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol. 2005;45(10):1570–1573
  41. Mintz GS, Tinana A, Hong MK, Lee CW, Kim JJ, Fearnot NE, et al. Impact of preinterventional arterial remodeling on neointimal hyperplasia after implantation of (non-polymer-encapsulated) paclitaxel-coated stents: a serial volumetric intravascular ultrasound analysis from the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation. 2003;108:1295–1298
  42. Morice MC for the REALITY investigators. Head to head comparison of C vs T stents, the REALITY study. In: Presented at ACC. Orlando. 2005;
  43. Winndecker S for the Sirtax investigators. SIRTAX. In: Presented at ACC. Orlando. 2005;
  44. Kastrati A for the Sirtax-Diabetes trial. ISAR-DIABETES Trial. In: Presented at ACC. Orlando. 2005;
  45. Suárez de Lezo J for the CORPAL investigators. DES for complex lesions: latest angiographic data from the randomized rapamycin vs paclitaxel CORPAL study. In: Presented at ACC. Orlando. 2005;
  46. Stone G for the TAXUS VI investigators. In: Presented at ACC. Orlando. 2005;
  47. Park SJ. In: Presented at ACC. Orlando. 2005;
  48. Gruberg L for the TAXUS CTO Register investigators. Paclitaxel eluting stents for treatment of complex lesions subsets: results of a TAXUS CTO Registry. In: Munich. European Society of Cardiology Congress. 2004;

PII: S1553-8389(05)00097-7

doi: 10.1016/j.carrev.2005.07.005

Cardiovascular Revascularization Medicine
Volume 6, Issue 3 , Pages 92-98 , July 2005

Article Tools